Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

  • 1
    Type of Publication: Journal article published
    PubMed ID: 23721604
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Abstract: This first German evidence-based guideline for cutaneous melanoma was developed under the auspices of the German Dermatological Society (DDG) and the Dermatologic Cooperative Oncology Group (DeCOG) and funded by the German Guideline Program in Oncology. The recommendations are based on a systematic literature search, and on the consensus of 32 medical societies, working groups and patient representatives. This guideline contains recommendations concerning diagnosis, therapy and follow-up of melanoma. The diagnosis of primary melanoma based on clinical features and dermoscopic criteria. It is confirmed by histopathologic examination after complete excision with a small margin. For the staging of melanoma, the AJCC classification of 2009 is used. The definitive excision margins are 0.5 cm for in situ melanomas, 1 cm for melanomas with up to 2 mm tumor thickness and 2 cm for thicker melanomas, they are reached in a secondary excision. From 1 mm tumor thickness, sentinel lymph node biopsy is recommended. For stages II and III, adjuvant therapy with interferon-alpha should be considered after careful analysis of the benefits and possible risks. In the stage of locoregional metastasis surgical treatment with complete lymphadenectomy is the treatment of choice. In the presence of distant metastasis mutational screening should be performed for BRAF mutation, and eventually for CKIT and NRAS mutations. In the presence of mutations in case of inoperable metastases targeted therapies should be applied. Furthermore, in addition to standard chemotherapies, new immunotherapies such as the CTLA-4 antibody ipilimumab are available. Regular follow-up examinations are recommended for a period of 10 years, with an intensified schedule for the first three years.
    Type of Publication: Journal article published
    PubMed ID: 24028775
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-1173
    Keywords: Schlüsselwörter ; Herpes gestationis ; Schwangerschaftsdermatose ; Bullöses Pemphigoid ; BP180 ; Pruritus ; Key words ; Herpes gestationis ; Dermatoses of pregnancy ; Bullous pemphigoid ; BP180 ; Pruritus
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary Background and Objective: Pemphigoid gestationis (PG) is a rare pregnancy-associated autoimmune bullous disease characterized by autoantibodies to the 180 kD bullous pemphigoid antigen (BP180). The clinical spectrum of PG is polymorphic and for diagnostic purposes, a skin biopsy is usually taken demonstrating the deposition of autoantibodies. Patients and Methods: From 2 patients, skin biopsies were obtained for histopathologic and immunofluorescence studies. Circulating autoantibodies were characterized by immunoblotting and ELISA using a recombinant form of the immunodominant BP180 NC16 A domain. Results: The 2 PG patients described here did not show blisters but complained about severe itching. In the first case, PG presented in the first trimester of the second pregnancy as an erythema-multiforme-like disease. The second patient developed urticarial plaques a few days after delivery. PG was diagnosed by the detection of autoantibodies against recombinant BP180 NC16 A by immunoblot and ELISA analysis and confirmed by linear deposits of C3 at the cutaneous basement membrane zone on direct immunofluorecence microscopy. Skin lesions healed with oral prednisolon. Conclusions: In our two patients, non-bullous PG could be diagnosed by serological tests. Immunmoblotting and ELISA might be sensitive and specific tools when screening sera of patients with pruritic skin lesions in pregnancy for the presence of autoantibodies to BP180. In some cases, these newer techniques may make a skin biopsy unnecessary.
    Notes: Zusammenfassung Hintergrund und Fragestellung: Das Pemphigoid gestationis (PG) ist eine seltene, schwangerschaftsspezifische Autoimmundermatose mit Autoantikörpern gegen das 180 kD bullöse Pemphigoid Antigen (BP180). Das klinische Bild ist polymorph. Die Diagnose des PG wird meist anhand einer Biopsie mit Nachweis der Autoantikörper in der Haut der Patientinnen gesichert. Patienten/Methodik: Bei 2 Patientinnen wurden Hautbiopsien histopatholgisch und immunfluoreszenzoptisch untersucht. Die Autoantikörper wurden mittels Immunoblot und ELISA unter Verwendung einer rekombinanten Form der immundominanten BP180-NC16-A-Domäne charakterisiert. Ergebnisse: Bei den beiden vorgestellten Patientinnen verlief das PG ohne Blasenbildung, jedoch mit starkem Juckreiz. Bei unserer ersten Patientin manifestierte sich die Erkrankung im 1. Trimenon unter dem Bild eines Erythema multiforme, der 2. Fall trat wenige Tage postpartal unter dem Bild einer Urtikaria auf. Die Diagnose wurde jeweils durch den Nachweis von Antikörpern gegen rekombinantes BP180 NC16 A im Immunoblot und ELISA und durch lineare C3-Ablagerungen an der Basalmembran in der direkten Immunfluoreszenz gesichert. Die Hautveränderungen heilten bei beiden Patientinnen unter oraler Prednisolontherapie ab. Schlussfolgerung: Bei den beiden vorgestellten Patientinnen wurde anhand von Serumuntersuchungen ein PG ohne Blasenbildung diagnostiziert. Sowohl Immunoblot als auch ELISA erscheinen aufgrund ihrer hohen Sensitivität und Spezifität als Screeningverfahren zum Nachweis von Autoantikörpern gegen BP180 bei pruriginösen Schwangerschaftsdermatosen geeignet. In der Zukunft dürften sie mitunter die bisher unverzichtbare Hautbiopsie zur Diagnose eines PG ersetzen.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...